| Date | Title | | | 08/24/10 | AVI BioPharma Announces Positive Results Against Human Pandemic H1N1
Influenza Virus in Preclinical Studies of AVI-7100| AVI-7100 Demonstrates Statistically Significant Activity Versus Saline and Tamiflu(R) Controls, Up to 3.9 Log Greater Reduction in Average Viral Titer AVI BioPharma and US Department of Defense Conduct Successful Rapid Response Exercise Against Real-World Threat, Pandemic H1N1 Virus
BOTHELL, WA, Aug 24, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced positive results from two preclinical studies
evaluating the therapeutic p... |
|  | | 08/23/10 | Nature Medicine Publishes AVI BioPharma Preclinical Studies
Demonstrating Post-Exposure Efficacy of PMOplus(TM) Oligomers Against
Ebola and Marburg Viruses| BOTHELL, WA, Aug 23, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced the publication online in Nature
Medicine of new preclinical data demonstrating that AVI-6002 and
AVI-6003, the respective lead therapeutic candidates against Ebola
and Marburg viruses, both employing AVI's advanced PMOplus(TM)
chemistry, provide post exposure efficacy in non-human primates.
Treatment of Ebola virus-infected primates with AVI-6002 l... |
| | | 08/09/10 | AVI BioPharma Announces Second Quarter 2010 Financial Results| Financial Results and Corporate Update Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific)
BOTHELL, WA, Aug 09, 2010 (MARKETWIRE via COMTEX) --
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and six months ended June 30, 2010.
For the second quarter of 2010 AVI reported an operating loss of $7.7 million compared with an operating loss of $5.1 million in the second quarter of 2009. The increase in the opera... |
| | | 08/02/10 | AVI BioPharma Announces Second Quarter 2010 Financial Results and
Corporate Update Conference Call| BOTHELL, WA, Aug 02, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, will report second quarter 2010 financial results after
the NASDAQ Global Market closes on Monday, August 9, 2010.
Subsequently, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time), J.
David Boyle II, AVI's Interim President and Chief Executive Officer,
and Chief Financial Officer, will host a conference call to discuss
second quarter 2010 financial results and to p... |
| | | 07/29/10 | AVI BioPharma to Present at BMO Capital Markets Focus on Healthcare
Conference| BOTHELL, WA, Jul 29, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, announced today that the company is scheduled to
present at the BMO Capital Markets 10th Annual Focus on Healthcare
Conference on Thursday, August 5, 2010, at 8:30 a.m. Eastern Time in
New York City. J. David Boyle II, AVI's Interim President and Chief
Executive Officer, and Chief Financial Officer, will provide a
company overview.
The conference presentation ... |
| | | 07/20/10 | AVI BioPharma Awarded up to $291 Million U.S. Government Contract for
Advanced Development of Therapeutic Candidates for Ebola and Marburg
Hemorrhagic Fever Viruses| Contract Largest Ever Awarded as Part of U.S. Department of Defense Transformational Medical Technologies Program; Conference Call Scheduled Tomorrow, Wednesday, July 21, 2010 at 11:00 a.m. Eastern Time to Provide Business Overview
BOTHELL, WA, Jul 20, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, announced that it has been awarded a new contract for
up to approximately $291 million total with the U.S. Department of
Defense Chemi... |
| | | 07/16/10 | AVI BioPharma Discloses New Contract With U.S. Government for
Potential Funding of up to $291 Million to Advance Development of
Therapeutic Candidates for Ebola and Marburg Hemorrhagic Fever
Viruses| BOTHELL, WA, Jul 16, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, yesterday filed a current report on Form 8-K with the
U.S. Securities and Exchange Commission providing the following
disclosure:
On July 14, 2010, AVI BioPharma, Inc. (the "Company") was awarded a
new contract with the U.S. Department of Defense Chemical and
Biological Defense Program through the U.S. Army Space and Missile
Defense Command for the advanced de... |
| | | 07/16/10 | AVI BioPharma Announces Presentations on Exon Skipping Drug AVI-4658
for Treatment of Duchenne Muscular Dystrophy at International
Congress on Neuromuscular Diseases| BOTHELL, WA, Jul 16, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced upcoming presentations on AVI-4658, the Company's
exon skipping therapy for the treatment of Duchenne muscular
dystrophy, at the XII International Congress on Neuromuscular
Diseases taking place July 17-22, 2010 in Naples, Italy. The
presentations will highlight results from Study 28, the recently
completed Phase 1b/2 clinical trial of AVI-4658.
Steph... |
| | | 07/07/10 | AVI BioPharma Opens Investigational New Drug (IND) Application for
AVI-4658 in Duchenne Muscular Dystrophy| BOTHELL, WA, Jul 07, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced that following review by the U.S. Food
and Drug Administration the Company's Investigational New Drug (IND)
application for AVI-4658 is open. AVI-4658 is AVI's lead drug
candidate being developed as a systemically administered treatment
for a substantial subgroup of patients with Duchenne muscular
dystrophy (DMD), a genetic muscle wasting disease ca... |
| | | 06/10/10 | AVI BioPharma to Present at ThinkEquity's Mid Year Check-Up on
Healthcare Conference| BOTHELL, WA, Jun 10, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, announced today that the company is scheduled to
present at ThinkEquity's Mid Year Check-Up on Healthcare Conference,
June 16, 2010, at 1:00 p.m. Eastern Time in New York City. J. David
Boyle II, AVI's Interim President and Chief Executive Officer, and
Chief Financial Officer, is scheduled to provide a company overview.
The conference presentation will be webcast... |
| | | 06/07/10 | AVI BioPharma Discloses New Contract With U.S. Government for up to
$18 Million to Advance Development of AVI-7100 as H1N1 Flu
Therapeutic| BOTHELL, WA, Jun 07, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today filed a current report on Form 8-K with the U.S.
Securities and Exchange Commission providing the following
disclosure:
On June 4, 2010, AVI BioPharma, Inc. (the "Company"), entered into a
new contract with the U.S. Defense Threat Reduction Agency ("DTRA")
to advance the development of AVI-7100, which was previously
designated AVI-7367 and which has been r... |
| | | 06/03/10 | AVI BioPharma to Present at the Jefferies 2010 Global Life Sciences
Conference| BOTHELL, WA, Jun 03, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
announced today that the company is scheduled to present at the
Jefferies 2010 Global Life Sciences Conference on Thursday, June 10,
2010, at 9:00 a.m., Eastern Time, in New York City. J. David Boyle
II, AVI's Interim President and Chief Executive Officer, and Chief
Financial Officer, is scheduled to provide a company overview.
The conference presentation will be webcas... |
| | | 06/02/10 | AVI-4658 Demonstrates First Ever Reported Generation of Greater Than
50% Dystrophin-Positive Muscle Fibers in a Patient Following Systemic
Administration in Duchenne Muscular Dystrophy; All Patients in Two
Highest Dose Cohorts Generated New Dystrophin-Positive Fibers| AVI-4658 Oligomer Demonstrates Dose Response Conference Call Scheduled Today at 8:30 AM Eastern Time
BOTHELL, WA, Jun 02, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced topline biopsy data from Study 28, the ongoing Phase
1b/2 clinical trial of AVI-4658, AVI's lead drug candidate being
developed as a systemically administered treatment for a substantial
subgroup of patients with Duchenne muscular dystrophy (DMD), a
gene... |
| | | 05/11/10 | AVI BioPharma to Present at the Rodman & Renshaw 6th Annual Global
Healthcare Conference| BOTHELL, WA, May 11, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
announced today that the company is scheduled to present at the
Rodman & Renshaw 6th Annual Global Healthcare Conference on Monday,
May 17, 2010, at 10:40 a.m., local time (5:40 a.m. Eastern Time), at
the Grosvenor House Hotel, Albemarle Suite, London, UK. J. David
Boyle II, AVI's Interim President and Chief Executive Officer, and
Chief Financial Officer, is scheduled... |
| | | 05/10/10 | AVI BioPharma Announces First Quarter 2010 Financial Results| Financial Results and Corporate Update Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific)
BOTHELL, WA, May 10, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today reported financial results for the three months ending March
31, 2010.
Revenues for the first quarter of 2010 were $1.2 million, down from
$3.1 million in the first quarter of 2009, reflecting a decrease in
government research contracts revenues of $1.9 mi... |
| | | 05/07/10 | AVI BioPharma and Collaborators Publish Data From Preclinical Studies
Demonstrating the Antimicrobial Efficacy of PMO Oligomers Against
Burkholderia Cepacia Complex in The Journal of Infectious Diseases| Also Published Is an Editorial, Beyond Antibiotics: New Horizons in Treating Burkholderia Species Infections, Commenting on the Studies
BOTHELL, WA, May 07, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
and its collaborators, including the National Institutes of Health,
today announced the publication online in The Journal of Infectious
Diseases of new data demonstrating the potential utility of
phosphorodiamidate morpholino oligomers ... |
| | | 05/03/10 | AVI BioPharma Announces First Quarter 2010 Financial Results and
Corporate Update Conference Call| BOTHELL, WA, May 03, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
will report first quarter 2010 financial results after the NASDAQ
Global Market closes on Monday, May 10, 2010. Subsequently, at 5:00
p.m. Eastern time (2:00 p.m. Pacific time), J. David Boyle II, AVI's
Interim President and Chief Executive Officer, and Chief Financial
Officer, will host a conference call to discuss the first quarter
2010 financial results and to provide ... |
| | | 04/28/10 | AVI BioPharma Secures Increased Funding of Approximately $4.0 Million
Under Its Contract With the U.S. Defense Threat Reduction Agency for
Development of Therapeutics Targeting H1N1 Swine Flu| BOTHELL, WA, Apr 28, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced it secured increased funding of up to approximately
$4.0 million under its agreement with the U.S. Defense Threat
Reduction Agency (DTRA) to develop, in cooperation with the
Transformational Medical Technologies Initiative (TMTI) of the
Department of Defense, one or more of AVI's nucleotide-based drug
candidates targeting the pandemic H1N1 influenza virus ... |
| | | 04/21/10 | AVI BioPharma Appoints David Boyle Interim President and CEO| Announces Agreement With Shareholder Group; New Independent Director, Anthony Chase, Joins AVI Board
BOTHELL, WA, Apr 21, 2010 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced that it has reached an agreement with Mr. George W.
Haywood, Ms. Cheryl Haywood, Rockall Emerging Markets Master Fund
Limited, Meldrum Asset Management, LLC, Mr. Con Egan and Mr. Conor
O'Driscoll ("the shareholder group"), which will result in changes to
... |
| | | 03/26/10 | AVI BioPharma Issues Statement Regarding Filing by Shareholder Group| BOTHELL, WA, Mar 26, 2010 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
issued the following statement regarding the Schedule 13D filed today
with the SEC by a group of AVI shareholders in which they stated that
they had requested a special meeting of shareholders:
"The AVI Board of Directors welcomes the views of all our
shareholders. We've had a productive dialogue with these
shareholders, which is continuing. We are carefully considering ... |
| | | 03/25/10 | AVI BioPharma Announces Update on AVI-5038, Its PPMO Duchenne
Muscular Dystrophy Drug Candidate, to Be Presented April 14, 2010 at
the American Academy of Neurology Annual Meeting| BOTHELL, WA, Mar 25, 2010 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced that on April 14, 2010, at the American Academy of
Neurology Annual Meeting (AAN), it will provide an update on the
preclinical evaluation of AVI-5038, its lead peptide-conjugated
morpholino-modified phosphorodiamidate oligomer (PPMO) drug candidate
for Duchenne muscular dystrophy. PPMOs are based on AVI's core
phosphorodiamidate morpholino oligomers chem... |
| | | 03/25/10 | AVI BioPharma Announces Pending Changes to Board of Directors| BOTHELL, WA, Mar 25, 2010 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced that Michael D. Casey and Christopher S. Henney, have
decided not to stand for re-election as directors of AVI at the end
of their current terms, which end following the 2010 Annual Meeting
of the Company's shareholders. The decisions of both Mr. Casey and
Dr. Henney were based solely on personal reasons and were not the
result of any disagreement with AV... |
| | | 03/16/10 | AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results| Financial Results and Corporate Update Conference Call Today at 8:30 a.m. Eastern time (5:30 a.m. Pacific)
For Immediate Release
BOTHELL, WA — March 16, 2010 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and twelve months ending December 31, 2009.
“We’ve achieved significant progress over the past year. Our DMD program delivered the first clinical evidence of efficacy in two trials and our biodefense business, based on pas... |
| | | 03/09/10 | AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call| For Immediate Release
BOTHELL, WA — March 9, 2010 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Tuesday, March 16, 2010. Subsequently, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time), Dr. Leslie Hudson, AVI’s President and Chief Executive Officer, and J. David Boyle II, AVI’s Senior Vice President and Chief Financial Officer, will host a conference call to discuss ... |
| | | 02/15/10 | AVI BioPharma Receives Grants Totaling $500,000 from CureDuchenne and the Foundation to Eradicate Duchenne to Support Continuing Development of Drug Candidates to Treat Duchenne Muscular Dystrophy| For Immediate Release
BOTHELL, WA — February 15, 2010 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that CureDuchenne and the Foundation to Eradicate Duchenne (FED), each awarded grants of $250,000 to AVI BioPharma to support continued research and development of the Company’s exon skipping drug candidates for the treatment of Duchenne Muscular Dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. Cure Duchenne and FED... |
| | | 02/05/10 | AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy| For Immediate Release
BOTHELL, WA — February 5, 2010 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic muscle wasting disease caused by failure to produce dystrophin. The orphan drug designation potentiall... |
| | | 02/04/10 | AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of Toxicology| For Immediate Release
BOTHELL, WA — February 4, 2010 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that the results and scientific findings of Good Laboratory Practice (GLP)-compliant safety pharmacology and genotoxicity evaluations of AVI-4658, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy (DMD), were published online in the International Journal of Toxicology. The publication, "Safety Pharmacology and... |
| | | 01/15/10 | TMTI Accomplishments Have Advanced the Nation's Ability to Successfully Counter an Emerging Biothreat | |
|
